中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

文献类型：期刊论文

作者Yang, Haiyan12; Xiang, Bing5; Song, Yuqin4; Zhang, Huilai3; Zhao, Weili1; Zou, Dehui2; Lv, Fangfang11; Guo, Wei13; Liu, Aichun10; Li, Caixia8
刊名BLOOD ADVANCES
出版日期2022-03-22
卷号6
ISSN号2473-9529
DOI10.1182/bloodadvances.2020003698
通讯作者Li, Yufu(liyufu439@126.com)
英文摘要The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients were enrolled in China after having progressed or not responded to prior therapy. At data cutoff, 4 patients continued treatment with 37 discontinuations. The median follow-up was 6.8 months, the ORR was 29.3%, and the complete response rate was 17.1%. Median DOR, PFS, and OS were 4.5, 2.8, and 8.4 months, respectively. Adverse events (AEs) leading to treatment discontinuation were reported in 4 patients, and grade $ 3 AEs were reported in 48.8% of patients. Major hemorrhage, atrial fibrillation, and/or flutter were not observed. Zanubrutinib demonstrated modest antitumor activity in non-GCB DLBCL, like other BTK inhibitors, as well as a safety profile consistent with previous studies. Through retrospective biomarker testing, potential antitumor activity was observed in patients with both CD79B and MYD88 mutations, who have inferior outcomes to immunochemotherapy. Future studies of zanubrutinib in R/R non-GCB DLBCL will focus on developing mechanism-based treatment combinations and biomarker-driven patient selection.
WOS关键词NON-HODGKIN-LYMPHOMA ; IMMUNOHISTOCHEMISTRY ; IBRUTINIB ; SURVIVAL
资助项目BeiGene ; BeiGene Ltd. (Shanghai, China) ; BeiGene USA, Inc. (San Mateo, CA)
WOS研究方向Hematology
语种英语
出版者ELSEVIER
WOS记录号WOS:000792486200001
资助机构BeiGene ; BeiGene Ltd. (Shanghai, China) ; BeiGene USA, Inc. (San Mateo, CA)
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/130923]  
专题中国科学院合肥物质科学研究院
通讯作者Li, Yufu
作者单位1.Shanghai Jiao Tong Univ, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom, Sch Med,Shanghai Inst Hematol,Ruijin Hosp, Shanghai, Peoples R China
2.Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Lymphoma Diag & Therapy Ctr, Tianjin, Peoples R China
3.Tianjin Med Univ Canc Inst & Hosp, Dept Lymphoma, Tianjin, Peoples R China
4.Beijing Canc Hosp, Dept Lymphoma, Beijing, Peoples R China
5.West China Hosp, Sichuan Hosp, Dept Hematol, Chengdu, Peoples R China
6.Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
7.BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
8.Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China
9.BeiGene USA Inc, San Mateo, CA USA
10.Harbin Med Univ, Canc Hosp, Dept Hematol & Lymphoma, Harbin, Peoples R China
推荐引用方式
GB/T 7714		 Yang, Haiyan,Xiang, Bing,Song, Yuqin,et al. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma[J]. BLOOD ADVANCES,2022,6.
APA Yang, Haiyan.,Xiang, Bing.,Song, Yuqin.,Zhang, Huilai.,Zhao, Weili.,...&Li, Yufu.(2022).Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.BLOOD ADVANCES,6.
MLA Yang, Haiyan,et al."Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma".BLOOD ADVANCES 6(2022).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。